Hesperidin RCT in MS
A Randomized, Placebo-Controlled Trial of Hesperidin for Fatigue,Mood, and Cognitive Function in Multiple Sclerosis
What it found
No result yet.
What was tested
Treatment tested
- Hesperidin
Placebo
- Placebo
What it measured
Main measures
Fatigue
Baseline and Week 12
Thinking and memoryFatigue
Other measures (2)
Mood and Stress
Baseline and Week 12
Mood and sleepCognitive Function Battery
Baseline and Week 12
Thinking and memoryFatigueMood and sleep
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* Diagnosis of Multiple Sclerosis, Aged 18 years or older.
Exclusion criteria
* Known food allergies, intolerances, or significant gastrointestinal (GI) problems, Participants under the age of 18 years.
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress. Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.
Loading reviews and guidelines…
History
Started
Jan 2026
Main results due
Jan 2027
Finished
Jan 2027